<?xml version="1.0" encoding="UTF-8" standalone="no"?><document id="DDI-DrugBank.d138">
    <sentence id="DDI-DrugBank.d138.s0" text="Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered.">
        <entity charOffset="72-81" id="DDI-DrugBank.d138.s0.e0" text="ALPHAGAN P" type="brand"/>
        <entity charOffset="143-157" id="DDI-DrugBank.d138.s0.e1" text="CNS depressants" type="group"/>
        <entity charOffset="160-166" id="DDI-DrugBank.d138.s0.e2" text="alcohol" type="drug"/>
        <entity charOffset="169-180" id="DDI-DrugBank.d138.s0.e3" text="barbiturates" type="group"/>
        <entity charOffset="183-189" id="DDI-DrugBank.d138.s0.e4" text="opiates" type="group"/>
        <entity charOffset="192-200" id="DDI-DrugBank.d138.s0.e5" text="sedatives" type="group"/>
        <entity charOffset="206-216" id="DDI-DrugBank.d138.s0.e6" text="anesthetics" type="group"/>
        <pair ddi="true" e1="DDI-DrugBank.d138.s0.e0" e2="DDI-DrugBank.d138.s0.e1" id="DDI-DrugBank.d138.s0.p0" type="advise"/>
        <pair ddi="true" e1="DDI-DrugBank.d138.s0.e0" e2="DDI-DrugBank.d138.s0.e2" id="DDI-DrugBank.d138.s0.p1" type="advise"/>
        <pair ddi="true" e1="DDI-DrugBank.d138.s0.e0" e2="DDI-DrugBank.d138.s0.e3" id="DDI-DrugBank.d138.s0.p2" type="advise"/>
        <pair ddi="true" e1="DDI-DrugBank.d138.s0.e0" e2="DDI-DrugBank.d138.s0.e4" id="DDI-DrugBank.d138.s0.p3" type="advise"/>
        <pair ddi="true" e1="DDI-DrugBank.d138.s0.e0" e2="DDI-DrugBank.d138.s0.e5" id="DDI-DrugBank.d138.s0.p4" type="advise"/>
        <pair ddi="true" e1="DDI-DrugBank.d138.s0.e0" e2="DDI-DrugBank.d138.s0.e6" id="DDI-DrugBank.d138.s0.p5" type="advise"/>
        <pair ddi="false" e1="DDI-DrugBank.d138.s0.e1" e2="DDI-DrugBank.d138.s0.e2" id="DDI-DrugBank.d138.s0.p6"/>
        <pair ddi="false" e1="DDI-DrugBank.d138.s0.e1" e2="DDI-DrugBank.d138.s0.e3" id="DDI-DrugBank.d138.s0.p7"/>
        <pair ddi="false" e1="DDI-DrugBank.d138.s0.e1" e2="DDI-DrugBank.d138.s0.e4" id="DDI-DrugBank.d138.s0.p8"/>
        <pair ddi="false" e1="DDI-DrugBank.d138.s0.e1" e2="DDI-DrugBank.d138.s0.e5" id="DDI-DrugBank.d138.s0.p9"/>
        <pair ddi="false" e1="DDI-DrugBank.d138.s0.e1" e2="DDI-DrugBank.d138.s0.e6" id="DDI-DrugBank.d138.s0.p10"/>
        <pair ddi="false" e1="DDI-DrugBank.d138.s0.e2" e2="DDI-DrugBank.d138.s0.e3" id="DDI-DrugBank.d138.s0.p11"/>
        <pair ddi="false" e1="DDI-DrugBank.d138.s0.e2" e2="DDI-DrugBank.d138.s0.e4" id="DDI-DrugBank.d138.s0.p12"/>
        <pair ddi="false" e1="DDI-DrugBank.d138.s0.e2" e2="DDI-DrugBank.d138.s0.e5" id="DDI-DrugBank.d138.s0.p13"/>
        <pair ddi="false" e1="DDI-DrugBank.d138.s0.e2" e2="DDI-DrugBank.d138.s0.e6" id="DDI-DrugBank.d138.s0.p14"/>
        <pair ddi="false" e1="DDI-DrugBank.d138.s0.e3" e2="DDI-DrugBank.d138.s0.e4" id="DDI-DrugBank.d138.s0.p15"/>
        <pair ddi="false" e1="DDI-DrugBank.d138.s0.e3" e2="DDI-DrugBank.d138.s0.e5" id="DDI-DrugBank.d138.s0.p16"/>
        <pair ddi="false" e1="DDI-DrugBank.d138.s0.e3" e2="DDI-DrugBank.d138.s0.e6" id="DDI-DrugBank.d138.s0.p17"/>
        <pair ddi="false" e1="DDI-DrugBank.d138.s0.e4" e2="DDI-DrugBank.d138.s0.e5" id="DDI-DrugBank.d138.s0.p18"/>
        <pair ddi="false" e1="DDI-DrugBank.d138.s0.e4" e2="DDI-DrugBank.d138.s0.e6" id="DDI-DrugBank.d138.s0.p19"/>
        <pair ddi="false" e1="DDI-DrugBank.d138.s0.e5" e2="DDI-DrugBank.d138.s0.e6" id="DDI-DrugBank.d138.s0.p20"/>
    <negationtags>Although specific drug interaction studies have &lt;scope&gt; &lt;cue&gt; not &lt;/cue&gt; been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered. &lt;/scope&gt;</negationtags></sentence>
    <sentence id="DDI-DrugBank.d138.s1" text="Alpha-agonists, as a class, may reduce pulse and blood pressure.">
        <entity charOffset="0-13" id="DDI-DrugBank.d138.s1.e0" text="Alpha-agonists" type="group"/>
    </sentence>
    <sentence id="DDI-DrugBank.d138.s2" text="Caution in using concomitant drugs such as beta-blockers (ophthalmic and systemic), anti-hypertensives and/or cardiac glycosides is advised.">
        <entity charOffset="43-55" id="DDI-DrugBank.d138.s2.e0" text="beta-blockers" type="group"/>
        <entity charOffset="84-101" id="DDI-DrugBank.d138.s2.e1" text="anti-hypertensives" type="group"/>
        <entity charOffset="110-127" id="DDI-DrugBank.d138.s2.e2" text="cardiac glycosides" type="group"/>
        <pair ddi="false" e1="DDI-DrugBank.d138.s2.e0" e2="DDI-DrugBank.d138.s2.e1" id="DDI-DrugBank.d138.s2.p0"/>
        <pair ddi="false" e1="DDI-DrugBank.d138.s2.e0" e2="DDI-DrugBank.d138.s2.e2" id="DDI-DrugBank.d138.s2.p1"/>
        <pair ddi="false" e1="DDI-DrugBank.d138.s2.e1" e2="DDI-DrugBank.d138.s2.e2" id="DDI-DrugBank.d138.s2.p2"/>
    </sentence>
    <sentence id="DDI-DrugBank.d138.s3" text="Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic clonidine.It is not known whether the concurrent use of these agents with ALPHAGAN P in humans can lead to resulting interference with the IOP lowering effect.">
        <entity charOffset="0-24" id="DDI-DrugBank.d138.s3.e0" text="Tricyclic antidepressants" type="group"/>
        <entity charOffset="89-97" id="DDI-DrugBank.d138.s3.e1" text="clonidine" type="drug"/>
        <entity charOffset="163-172" id="DDI-DrugBank.d138.s3.e2" text="ALPHAGAN P" type="brand"/>
        <pair ddi="true" e1="DDI-DrugBank.d138.s3.e0" e2="DDI-DrugBank.d138.s3.e1" id="DDI-DrugBank.d138.s3.p0" type="effect"/>
        <pair ddi="false" e1="DDI-DrugBank.d138.s3.e0" e2="DDI-DrugBank.d138.s3.e2" id="DDI-DrugBank.d138.s3.p1"/>
        <pair ddi="false" e1="DDI-DrugBank.d138.s3.e1" e2="DDI-DrugBank.d138.s3.e2" id="DDI-DrugBank.d138.s3.p2"/>
    <negationtags>Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic clonidine.It is &lt;scope&gt; &lt;cue&gt; not &lt;/cue&gt; known whether the concurrent use of these agents with ALPHAGAN P in humans can lead to resulting interference with the IOP lowering effect. &lt;/scope&gt;</negationtags></sentence>
    <sentence id="DDI-DrugBank.d138.s4" text="No data on the level of circulating catecholamines after ALPHAGAN P administration are available.">
        <entity charOffset="57-66" id="DDI-DrugBank.d138.s4.e0" text="ALPHAGAN P" type="brand"/>
    <negationtags>&lt;scope&gt; &lt;cue&gt; No &lt;/cue&gt; data on the level of circulating catecholamines after ALPHAGAN P administration are available. &lt;/scope&gt;</negationtags></sentence>
    <sentence id="DDI-DrugBank.d138.s5" text="Caution, however, is advised in patients taking tricyclic antidepressants which can affect the metabolism and uptake of circulating amines.">
        <entity charOffset="48-72" id="DDI-DrugBank.d138.s5.e0" text="tricyclic antidepressants" type="group"/>
    </sentence>
</document>